Wallaby Medical Holding, Inc.

Wallaby Medical Holding, Inc., established in December 2015, develops innovative neurointerventional solutions for treatment of cerebrovascular and neurovascular diseases, with a strategic focus on stroke management. In April 2022, the company acquired phenox GmbH, a global neurointerventional leader based in Germany, significantly expanding its product portfolio and global reach. The combined organization now operates 5 R&D centers and 3 manufacturing facilities across multiple continents, employing over 700 personnel worldwide, with a major presence in Shanghai (17,000+ square meters) and headquarters in Laguna Hills, California. The company's core product lines include the Avenir® Coil System (detachable coils for aneurysm treatment), Esperance™ Aspiration Catheters (5F and 6F configurations for thrombectomy), pRESET Thrombectomy Device (stentriever), and pEGASUS HPC Stent System (laser-cut, open-cell design with antithrombogenic coating). Products have received FDA 510(k) clearance, NMPA (China) approval, and regulatory clearance in 60+ countries. The company maintains active distribution networks in Japan, Brazil, South Korea, and other markets. Manufacturing and R&D capabilities support both proprietary development and acquired product lines.